StreetInsider.com News Articles

Form 10-Q AVENUE THERAPEUTICS, For: Mar 31

Fri, 08 May 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260508/26458335.html

Form 10-Q AVENUE THERAPEUTICS, For: Mar 31

Fri, 08 May 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260508/26458335.html

Form 10-K AVENUE THERAPEUTICS, For: Dec 31

Mon, 30 Mar 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260330/26241522.html

Form 10-K AVENUE THERAPEUTICS, For: Dec 31

Mon, 30 Mar 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260330/26241522.html

Form 8-K AVENUE THERAPEUTICS, For: Feb 18

Mon, 23 Feb 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260223/26043206.html

Form 8-K AVENUE THERAPEUTICS, For: Feb 18

Mon, 23 Feb 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260223/26043206.html

Avenue Therapeutics licenses ATX-04 from Duke for Pompe disease treatment

Mon, 23 Feb 2026 08:00:23 -0400

Avenue Therapeutics Inc. (OTC: ATXI) announced it has entered into an exclusive worldwide license agreement with Duke University for ATX-04, a treatment for Pompe disease. The agreement covers patents and know-how for the drug, also known as clenbuterol.

ATX-04 is a selective β2-adrenergic agonist that has demonstrated improvements in muscle function in clinical studies. A study conducted at Duke University showed the treatment resulted in improvements in six-minute walk distance and increased respiratory muscle strength in Pompe disease patients receiving enzyme replacement therapy.

Pompe disease is a rare inherited disorder caused by deficiency of the enzyme acid α-glucosidase, resulting in progressive skeletal

Avenue Therapeutics licenses ATX-04 from Duke for Pompe disease treatment

Mon, 23 Feb 2026 08:00:23 -0400

Pompe disease is a rare inherited disorder caused by deficiency of the enzyme acid α-glucosidase, resulting in progressive skeletal

Form SCHEDULE 13G/A AVENUE THERAPEUTICS, Filed by: Ikarian Capital, LLC

Tue, 17 Feb 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260217/26014990.html

Form SCHEDULE 13G/A AVENUE THERAPEUTICS, Filed by: Ikarian Capital, LLC

Tue, 17 Feb 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260217/26014990.html

Form SCHEDULE 13D/A AVENUE THERAPEUTICS, Filed by: Fortress Biotech, Inc.

Tue, 06 Jan 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260106/25813386.html

Form 4 AVENUE THERAPEUTICS, For: Jan 02 Filed by: Fortress Biotech, Inc.

Tue, 06 Jan 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260106/25813195.html

Form 8-K AVENUE THERAPEUTICS, For: Dec 30

Wed, 31 Dec 2025 09:21:00 -0400

si-local-file:///var/storage/secattach/20251231/25792929.html

Form EFFECT AVENUE THERAPEUTICS,

Wed, 17 Dec 2025 06:02:00 -0400

si-local-file:///var/storage/secattach/20251217/25749353.html

Form POS AM AVENUE THERAPEUTICS,

Mon, 15 Dec 2025 17:23:00 -0400

si-local-file:///var/storage/secattach/20251215/25741791.html

Form RW AVENUE THERAPEUTICS,

Mon, 15 Dec 2025 16:07:00 -0400

si-local-file:///var/storage/secattach/20251215/25740678.html

Form DEF 14A AVENUE THERAPEUTICS, For: Dec 30

Fri, 05 Dec 2025 16:02:00 -0400

si-local-file:///var/storage/secattach/20251205/25706207.html

Form 8-K AVENUE THERAPEUTICS, For: Nov 14

Tue, 18 Nov 2025 17:17:00 -0400

si-local-file:///var/storage/secattach/20251118/25633186.html

Form 10-Q AVENUE THERAPEUTICS, For: Sep 30

Thu, 13 Nov 2025 16:10:00 -0400

si-local-file:///var/storage/secattach/20251113/25607363.html

Form 8-K AVENUE THERAPEUTICS, For: Nov 05

Wed, 12 Nov 2025 08:01:00 -0400

si-local-file:///var/storage/secattach/20251112/25592918.html

Axsome Therapeutics acquires epilepsy drug candidate from AstraZeneca

Thu, 06 Nov 2025 07:02:03 -0400

Axsome Therapeutics Inc. (NASDAQ: AXSM) acquired exclusive global rights to AZD7325, an oral epilepsy drug candidate, through a licensing agreement with AstraZeneca AB (NASDAQ: AZN). The transaction was completed by Axsome's acquisition of Baergic Bio Inc., a subsidiary of Avenue Therapeutics Inc. (OTC: ATXI).

AZD7325 is a GABA-A receptor positive allosteric modulator that has completed Phase 1 trials and been tested in over 700 patients. The drug demonstrated anti-convulsant effects in preclinical seizure models and showed a favorable safety and tolerability profile in clinical studies, according to the company's statement.